Paz-Ares's Lab

Research group @CNIOStopCancer and H12O led by @LuisPaz_Ares. Exploring new therapies for lung cancer. Tweets by Itziar Otano

[SOSCLC_AECC @SOSCLC_AECC]

💚 Día Mundial Sin Tabaco 💚
Cambia el humo por aire. Dejar de fumar, o no empezar nunca, es uno de los mayores regalos para nuestra salud y nuestros pulmones.
Desde SOSCLC-AECC seguimos impulsando la investigación, la prevención y la concienciación frente al cáncer de pulmón.💚

[SOSCLC_AECC @SOSCLC_AECC]

Celebrado el III Strategic Scientific Committee Meeting de SOSCLC-AECC en el Hospital 12 de Octubre.

Investigadores e IPs de todos los Work Packages se reunieron presencialmente y online para compartir avances y seguir impulsando la investigación en cáncer de pulmón microcítico.

[Abner Antonio Murray, MD PhD @dominicandoc2]

Excellent translational work from @BrunaPellini et al.

🔑: resistance after #KRAS #G12C inhibition may create new therapeutic vulnerabilities rather than simply closing doors. 🚪

‼️ Implications for #ADC combinations, #HER2 assessment in #NSCLC, and post-KRAS inhibitor treatment strategies. Worth reading. 📖

🤔Could adaptive HER2 upregulation become a clinically useful biomarker, or is HER2 scoring in #lungcancer still too variable? 🧬 🫁

@KRASKickers @Exon20Group @LUNGevity

#LCSM #KRASG12C @ChristianRolfo

[Paz-Ares's Lab @PazAresLab]

🟢Our last paper has been published in Journal of Thoracic Oncology. Robust preclinical and early clinical data on a promising new strategy combining Irinotecan and Lurbinectedin for the treatment of SCLC
https://t.co/Lers9b5Btd
@ashfromamike @IreneFerrerS @LuisPaz_Ares

[Klebanoff_Lab @KlebanoffLab]

👉Clinical validation that T stem cell (TSCM) memory CD8+ T cells mediate superior persistence and antitumor immunity following adoptive transfer. Congrats to Gattinoni et al. for bringing this seminal discovery full circle🧬! @uni_regensburg

https://t.co/goX54fI1pS

[Charles Swanton @CharlesSwanton]

Online here: https://t.co/nzzWChWPkD
Open access here: https://t.co/MEUA5HUeGx
Key supporters of this work are @CR_UK , @CRUKLungCentre , @UCLHresearch alongside many others

[Hospital Universitario 12 de Octubre @H12Octubre]

♋ Si eres paciente de cáncer o familiar y quieres saber cómo se impulsa, organiza y valora la investigación clínica en oncología, quizás te interese:

✅ #H12O y AECC te invitan a un encuentro con investigadores.

🗓️ 26 Mayo. 11-14h.

#somosdel12

⏩ https://t.co/iREY7lJQQw

[Garcia-Carbonero's Lab @GCarboneroLab]

🚨 #Hiring: Staff Scientist/Postdoc (Non-PI) – Madrid 🇪🇸

Translational oncology: tumor biology, biomarkers & precision medicine.

PhD + experience in molecular biology & preclinical models required.

👉 Apply
[email protected]
[email protected]

[Asociación Española Contra el Cáncer @ContraCancerEs]

Hoy celebramos el talento, la dedicación y la mirada de tantas mujeres que están cambiando el futuro de la #investigación.
En @contracancerES apoyamos a 420 investigadoras, con una inversión de 68 millones de euros.
#DiaInternacionaldelamujer #8M

[ACIR @ACIR_org]

Based on the randomized phase 3 LungTIME-C01 trial, Huang et al. reported that early time of day (ToD) treatment (before 3 pm) for the first 4 doses improved anti-PD-1 efficacy compared with late ToD treatment (after 3 pm) in patients with stage IIIC–IV NSCLC. For the early ToD group, median PFS and OS were 11.3 and 28.0 months, compared to the late ToD group, which were 5.7 and 16.8 months, respectively. Between both groups, no differences in incidence of immune-related adverse events were observed. Circulating CD8+ T cells increased in the early ToD group, with a higher activated (CD38+ HLA-DR+) versus exhausted (TIM-3+PD-1+) ratio. https://t.co/zQM5XTpmG2

[Global Immunotalks @globalimmuno]

Global Immunotalks 2026 has just begun!

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. https://t.co/LVGVrsv6H5

[CRIS Contra el Cáncer @criscancer]

🔴Cuando decimos que la investigación puede cambiar la historia, hablamos de días como hoy.

El Dr. #MarianoBarbacid y su equipo han logrado la desaparición completa y duradera del #CáncerdePáncreas en modelos experimentales

👉 https://t.co/09Fi0MVdqG

[Open Box Science @OpenBoxSci]

TOMORROW AT 5PM ET
Lymph nodes as hubs for productive CD8 T cell immunity

📢Two papers from @KalliesLab @TheDohertyInst @UniMelb in @NatImmunol (2025)!
Jan 22, 2026 | ⏰5pm ET/ 4pm CT/ 2pm PT

🔬Sharanya Wijesinghe
🧪Carlson Tsui
🎙️@dmcmanus123
Zoom:
https://t.co/OBmmVlGLVl

[Global Immunotalks @globalimmuno]

2026 is here! We’re excited to share Global Immunotalks first semester poster, featuring an outstanding lineup!

Please share and help us spread the word!

[Nature Rev Immunol @NatRevImmunol]

Inflame and restrain — the paradoxical roles of IL-12 and IL-23 in immunity https://t.co/j86syLPlXE

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8+ T cell responses https://t.co/MH5lQvHMLw

[Hospital Universitario 12 de Octubre @H12Octubre]

🍾 @LuisPaz_Ares, @JRperalto y Alberto Galindo, jefes de servicio del #H12O, médicos con la mayor reputación de España en 2025 en su especialidad

✅ Oncología Médica, Anatomía Patológica y Obstetricia y Ginecología

👏🏻 Enhorabuena. + info: https://t.co/roWj6gOvuU

#somosdel12

[Fernando Martín Moro @Fer_martinmoro]

@helenabotedcabo, oncóloga del @H12Octubre, habla para la revista @Mujerhoy acerca de las diferencias de género en #cáncer de pulmón 🫁 @PhrmMar
https://t.co/GQ0oPpgE3l

[Open Box Science @OpenBoxSci]

Don't miss the Nature Reviews Immunology webinar on new T cell nomenclature guidelines!

Monday, Dec 8, 2025
09:00 PST | 12:00 EST | 17:00 GMT | 18:00 CET

Register here: https://t.co/pe6GYY4AsS